BioCentury
ARTICLE | Clinical News

Catioprost: Phase II data

September 12, 2011 7:00 AM UTC

A single-blind, U.S. Phase II trial in 105 patients with glaucoma or ocular hypertension and ocular surface disease showed that once-daily Catioprost was non-inferior to Travatan Z travoprost in reduc...